PuraVIHta
Impact of Hypovitaminosis D in Metabolic Disturbances and Bone Metabolism, and Changes in Patients Receiving Vitamin D Supplementation
Sponsor study identifier
observational
300
1 country
1
Study Start
January 12, 2019
Actual (reported)Primary Completion
November 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
To determine the prevalence of hypovitaminosis D in HIV infected patients, and the consequences on secondary hyperparathyroidism, and bone mineral density (BMD). Also, to establish the improvement in vitamin D status, parathyroid hormone (PTH) and BMD, in case of receiving vitamin D supplementation, during a follow up period of at least 1 year.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 23, 2015
Actual (reported)January 30, 2015
Actual (reported)January 12, 2019
Actual (reported)November 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Prevalence of osteopenia/osteoporosis and secondary hyperparathyroidism in HIV infected patients according to vitamin D strata
Percentage of patients with high PTH and reduced BMD in each vitamin D strata (\< 10 ng/ml, 10-20 ng/ml, 20-30 ng/ml, \> 30 ng/ml)
48 weeks
Changes in vitamin D levels secondary to seasonality
48 weeks
Efficacy of supplementation in reducing secondary hyperparathyroidism and osteopenia/osteoporosis
48 weeks
Impact of vitamin D levels (25OHD) in reducing phosphaturia levels
48 weeks
Correlation between values of bone biomarkers (osteocalcin, beta-crosslaps, alkaline phosphatase, P1NP) and rates of osteopenia/osteoporosis
48 weeks
Measurement of vitamin D, PTH, and BMD changes in HIV-infected patients
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
HIV-infected patients in follow up
Ramon y Cajal Hospital
Madrid, 28034, Spain
Sara Bañon, MD
Ramon y Cajal Hospital
First Submitted
January 23, 2015
First Posted
January 30, 2015
Study Start
January 12, 2019
Actual (reported)Primary Completion
November 2022
Estimated (date passed)Comparing a Novel Phototherapy Kiosk to Oral Vitamin D Supplementation
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
October 18, 2022
Record last verified: 2022-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: